Liver tumors and host defense

Seminars in Liver Disease

Volumn 17, Issue 4, 1997, Pages 351-355

  Tabor, Edward ^a  

^a CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

Author keywords

Cytotoxic T lymphocytes; LAK cells; p53; Thrombomodulin; Transforming growth factor

Indexed keywords

ANTICOAGULANT AGENT; CELL PROTEIN; DNA; MUTANT PROTEIN; PROTEIN P53; THROMBOMODULIN; TRANSFORMING GROWTH FACTOR BETA1; VIRUS PROTEIN;

APOPTOSIS; CELL CYCLE; CELLULAR IMMUNITY; DNA SYNTHESIS INHIBITION; GENE MUTATION; HOST RESISTANCE; HUMAN; HUMORAL IMMUNITY; LIVER CELL CARCINOMA; MITOSIS INHIBITION; PRIORITY JOURNAL; REVIEW; TUMOR SUPPRESSOR GENE;

EID: 0030712355     PISSN: 02728087     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2007-1007212     Document Type: Review

References (51)

1. Finlay CA, Hinds PW, Levine AJ. The p53 proto-oncogene can act as a suppressor of transformation. Cell 57:1083-1093, 1989.
2. Puisieux A, Ponchel F, Ozturk M. p53 as a growth suppressor gene in HBV-related hepatocellular carcinoma cells. Oncogene 8:487-490, 1993.
3. Takahashi T, Carbone D, Takahashi T, et al. Wild-type but not mutant p53 suppresses the growlh of human lung cancer cells bearing multiple genetic lesions. Cancer Res 52:2340-2343, 1992.
4. Donehower LA, Harvey M, Slagle BL, et al. Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumours. Nature 356:215-221, 1992.
5. Malkin D, Li FP, Strong LC, et al. Germ line p53 mutations in a familial syndrome of breast cancer, sarcomas, and other neoplasms. Science 250:1233-1238, 1990.
6. Chen X, Bargonetti J, Prives C. p53, through p21 (WAFI/CIP1). induces cyclin D1 synthesis. Cancer Res 55:4257-4263, 1995.
7. Pagano M, Theodoras AM, Tam SW, et al. Cyclin D1-mediated inhibition of repair and replicative DNA synthesis in human fibroblasts. Genes Dev 8:1627-1639, 1994.
8. Bressac B, Kew M, Wands J, et al. Selective G to T mutations of p53 gene in hepatocellular carcinoma from southern Africa. Nature 350:429-431, 1991.
9. Hsu IC, Metcalf RA, Sun T, et al. Mutational hotspot in the p53 gene in human hepatocellular carcinomas. Nature 350:427-428, 1991.
10. Puisieux A, Jingwei J, Guillot C, et al. p53-mediated cellular response to DNA damage in cells with replicative hepatitis B virus. Proc Natl Acad Sci USA 92:1342-1346, 1995.
11. Feitelson MA, Zhu M. Duan L-X, et al. Hepatitis B x antigen and p53 are associated in vitro and in liver tissues from patients with primary hepatocellular carcinoma. Oncogene 8: 1109-1117, 1993.
12. Wang XW, Forrester K, Yeh H, et al Hepatitis B virus X protein inhibits p53 sequence-specific DNA binding, transcriptional activity, and association with transcription factor ERCC3. Proc Natl Acad Sci USA 91:2230-2234, 1994.
13. Truant R, Antunovic J, Greenblatt J, et al. Direct interaction of the hepatitis B virus HBx protein with p53 leads to inhibition by HBx of p53 response element-directed transactivation. J Viral 69:1851-1859, 1995.
14. Ucda H, Ulrich SJ, Gangemi JD, et al. Functional inactivation but not structural mutation of p53 causes liver cancer. Nature Genet 9:41-47, 1995.
15. Wang XW, Gibson MK, Vermeulen W, et al. Abrogation of p53-induced apoptosis by the hepatitis B virus X gene. Cancer Res 55:6012-6016, 1995.
16. Moll UM, La Quaglia M, Bénard J, et al. Wild-type p53 protein undergoes cytoplasmic sequestration in undifferentiated neuroblastomas but not in differentiated tumors. Proc Natl Acad Sci USA 92:4407-4411, 1995.
17. Moll UM, Riou G, Levine AJ. Two distinct mechanisms alter p53 in breast cancer: Mutation and nuclear exclusion. Proc Natl Acad Sci USA 89:7262-7266, 1992.
18. Takada S, Kaneniwa N, Tsuchida N, et al. Hepatitis B virus X gene expression is activated by X protein but repressed by p53 tumor suppressor gene product in the transient expression system. Virology 216:80-89, 1996
19. Abarzúa P, LoSardo JE, Gubler ML, et al. Microinjection of monoclonal antibody PAb421 into human SW480 colorectal carcinoma cells restores the transcription activation function to mutant p53 Cancer Res 55:3490-3494, 1995
20. Hamada K, Alemany R, Zhang W-W, et al. Adenovirus-mediated transfer of a wild-type p53 gene and induction of apoptosis in cervical cancer. Cancer Res 56:3047-3054, 1996.
21. Rosenfeld MR, Meneses P, Dalmau J, et al. Gene transfer of wild-type p53 results in restoration of tumor suppressor function in a medulloblastoma cell line. Neurology 45:1533-1539, 1995.
22. Roth JA, Nguyen D, Lawrence DD, et al. Retrovirus-mediated wild-type p53 gene transfer to tumors of patients wilh lung cancer Nature Med 2:989-991, 1996.
23. Anscher MS, Crocker IR, Jirtle RL. Transforming growth factor-ß1 expression in irradiated liver. Radiat Res 122:77-85, 1990.
24. Czaja MJ, Flanders KC, Biempica L, et al. Expression of tumor necrosis factor-α and transforming growth factor-ß1 in acute liver injury. Growth Factors 1:219-226, 1989.
25. Castilla A, Prieto J, Fausto N. Transforming growth factors ß1 and α in chronic liver disease. N EngL J Med 324:933-940, 1991.
26. Braun L, Mead JE, Panzica M, et al. Transforming growth factor ß mRNA increases during liver regeneration: A possible paracrine mechanism of growth regulation. Proc Natl Acad Sci USA 85:1539-1543, 1988.
27. Derynck R, Goeddel DV, Ullrich A, et al. Synthesis of messenger RNAs for transforming growth factors α and ßand the epidermal growth factor receptor by human tumors. Cancer Res 47:707-712, 1987.
28. Ito N, Kawata S, Tamura S, et al. Expression of transforming growth factor-ß1 mRNA in human hepatocellular carcinoma. Jpn J Cancer Res 81:1202-1205, 1990.
29. Shinazuka H, Kubo Y, Katyal SL, et al. Roles of growth factors and of tumor necrosis factor-alpha on liver cell proliferation induced in rats by lead nitrate. Lab Invest 71:35-41, 1995.
30. Cair BI, Hayashi I, Branum EL, et al. Inhibition of DNA synthesis in rat hepatocytes by platelet-derived type ß transforming growth factor. Cancer Res 46:2330-2334, 1986.
31. Nakao K, Nakata K, Mitsuoka S, et al. Transforming growth factor ß1 differentially regulates α-fetoprotein and albumin in HuH-7 human hepatoma cells. Biochem Biophys Res Commun 174:1294-1299, 1991.
32. Russell WE, Coffey RJ, Ouellette AJ, et al. Type ß transforming growth factor reversibly inhibits the early proliferative response to partial hepatectomy in the rat. Proc Natl Acad Sci USA 85:5126-5130, 1988.
33. Oberhammer F, Bursch W, Tiefenbacher R, et al. Apoptosis is induced by transforming growth factor -ß1 within 5 hours in regressing liver without significant fragmentation of the DNA. Hepatology 18:1238-1246, 1993
34. Lin J-K, Chou C-K. In vitro apoptosis in the human hepatoma cell line induced by transforming growth factor ß1. Cancer Res 52:385-388, 1992.
35. Ponchel F, Puisieux A, Tabone E, et al. Hepatocarcinoma-specific mutant p53-249ser induces mitotic activity but has no effect on transforming growth factor ß1-mediated apoptosis. Cancer Res 54:2064-2068, 1994
36. Raynal S, Jullien P, Lawrence DA. Transforming growth factor-ß enhances serum-induced dephosphorylation of the p53 protein in cell lines growth-inhibited by this factor. Growth Factors 11:197-203, 1994.
37. Shirai Y, Kawata S, Ito N, et al Elevated levels of plasma transforming growth factor-ß in patients with hepatocellular carcinoma. Jpn J Cancer Res 83:676-679, 1992.
38. Shirai Y, Kawata S, Tamura S, et al. Plasma transforming growth factor-ß1 in patients with hepatocellular carcinoma. Comparison with chronic liver diseases. Cancer 73:2275-2279, 1994
39. Guo Y-J, Wu M-C. Local immune response in hepatocellular carcinoma and its clinical implication. Chin Med J 101:685-688, 1988.
40. Kawata A, Une Y, Hosokawa M, et al. Tumor-infiltrating lymphocytes and prognosis of hepatocellular carcinoma. Jpn J Clin Oncol 22:256-263, 1992.
41. Usuda S, Yoshizawa K, Yabu K, et al. Immunological responses against an autologous human hepatocellular carcinoma cell line. J Gastroenterol Hepatol 8:517-523, 1993.
42. Paroli M, Carloni G, Franco A, et al. Human hepatoma cells expressing HLA class I molecules stimulate primary responses of purified CD8+ T lymphocytes. Res Virol 144:327-332,1993.
43. Shirai M, Watanabe S, Nishioka M Defective immunological functions associated with abnormal lymphokine-activated killer activity in patients with hepatocellular carcinoma. J Gastroenterol Hepatol 5:542-548, 1990.
44. Chu M-HH, Chien S-C, Hu C-P, et al. Natural and activated cytotoxic lymphocytes reactivity to human hepatocellular carcinoma cell lines in hepatocellular carcinoma patients. Liver 8:198-207, 1988.
45. Olubuyide IO, Salimonu LS, Adeniran SO. Soluble immune complexes and immunoglobulin (IgG, IgA and IgM) levels in Nigerians with primary liver cell carcinoma. Afr J Med Sci 22:57-62, 1993.
46. Suehiro S, Shimada M, Matsumata T, et al. Thrombomodulin inhibits intrahepatic spread in human hepatocellular carcinoma. Hepatology 21: 1285-1290, 1995.
47. Hasui Y, Marutsuka K, Suzumiya J, et al. The content of urokinase-type plasminogen activator antigen as a prognostic factor in urinary bladder cancer. Int J Cancer 50:871-873, 1992.
48. Marutsuka K, Suzumiya J, Kataoka H, et al. Correlation between urokinase-type plasminogen activator production and the metastatic ability of human rectal cancer cells. Invasion Metastasis 11:181-191, 1991.
49. Zacharski LR, Henderson WG, Rickles FR, et al. Effect of warfarin anticoagulation on survival in carcinoma of the lung, colon, head and neck, and prostate: Final report of VA Cooperative Study #75. Cancer 53:2046-2052, 1984.
50. Sheu J, Huang G, Lee P, et al. Mutation of p53 gene in hepatocellular carcinoma in Taiwan. Cancer Res 52:6098-6100, 1992.
51. Murakami Y, Hayashi K, Hirohashi S, et al: Aberrations of the tumor suppressor p53 and retinoblastoma genes in human hepatocellular carcinoma. Cancer Res 51:5520-5525, 1991.